Fig. 5
From: ALDH1A3 induces mesenchymal differentiation and serves as a predictor for survival in glioblastoma
The novel molecular classification scheme based on ALDH1A3-derived PMT genes. a Landscape of clinical features in different molecular classification groups in GBM patients of CGGA database. b Kaplan–Meier survival analysis showed that patients with high risk of the molecular classification scheme conferred a worse prognosis in GBM patients of CGGA, TCGA, GSE16011, and REMBRANDT databases. c Univariate and multivariate COX analysis showed that the molecular classification scheme was an independent prognostic factor in GBM patients of CGGA database. d The molecular classification scheme could accurately predict survival rate of GBM patients of CGGA and TCGA databases. e, f GSEA showed that GBM patients with high risk score were highly enriched in MES subtype and low risk patients were most enriched in PN subtype. g–i The Kaplan–Meier estimates of overall survival in GBM patients from CGGA and TCGA database illustrate survival according to risk-score and postoperative treatment strategies for the standard chemoradiotherapy subgroup (g), the radiotherapy alone subgroup (h), and all patients combined (i)
